Gut microbiome development along the colorectal adenoma-carcinoma sequence
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
Experiment 1
Subjects
- Location of subjects
- Austria
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Colorectal adenoma adenoma of large bowel,adenoma of large intestine,adenoma of the large bowel,adenoma of the large intestine,colorectal adenoma,colorectum adenoma,large bowel adenoma,large intestine adenoma,Colorectal adenoma
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Healthy Controls
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Advanced Colorectal Adenoma
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- colorectal adenoma patients The study was conducted both in participants of a health screening programme according to national screening recommendations for CRC49 as well as in patients with suspected CRC undergoing colonoscopy as part of the clinical workup at the Department of Internal Medicine, Oberndorf Hospital.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 55
- Group 1 sample size Number of subjects in the case (exposed) group
- 42
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 3 months
Lab analysis
- Sequencing type
- WMS
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Mann-Whitney (Wilcoxon)
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Richness Number of species
- unchanged
Signature 1
Source: Figure 4a
Description: Control versus advanced adenoma (n = 55 and 42).
Abundance in Group 1: increased abundance in Advanced Colorectal Adenoma
NCBI | Quality Control | Links |
---|---|---|
Paraprevotella clara | ||
Phocaeicola dorei | ||
Phocaeicola massiliensis |
Revision editor(s): Jeshudy
Signature 2
Source: Figure 4a
Description: Control versus advanced adenoma (n = 55 and 42).
Abundance in Group 1: decreased abundance in Advanced Colorectal Adenoma
NCBI | Quality Control | Links |
---|---|---|
Bifidobacterium animalis | ||
Streptococcus mutans |
Revision editor(s): Jeshudy
Experiment 2
Subjects
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Colorectal cancer cancer of colorectum,cancer of large bowel,cancer of large intestine,cancer of the large bowel,colon cancer,colorectal cancer,colorectum cancer,CRC,large intestine cancer,malignant colorectal neoplasm,malignant colorectal tumor,malignant colorectum neoplasm,malignant large bowel neoplasm,malignant large bowel tumor,malignant large intestine neoplasm,malignant large intestine tumor,malignant neoplasm of colorectum,malignant neoplasm of large bowel,malignant neoplasm of large intestine,malignant neoplasm of the large bowel,malignant neoplasm of the large intestine,malignant tumor of large bowel,malignant tumor of large intestine,malignant tumor of the large bowel,malignant tumor of the large intestine,Colorectal cancer
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Colorectal Cancer
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- colorectal cancer patients The study was conducted both in participants of a health screening programme according to national screening recommendations for CRC49 as well as in patients with suspected CRC undergoing colonoscopy as part of the clinical workup at the Department of Internal Medicine, Oberndorf Hospital.
- Group 1 sample size Number of subjects in the case (exposed) group
- 41
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Richness Number of species
- increased
Signature 1
Source: Figure 4c
Description: Control versus carcinoma (n = 55 and 41). For all MLGs containing >100 genes, the direction of enrichment was determined by Wilcoxon rank-sum test (P < 0.05, Supplementary Data 3). Size of the nodes scales with the number of genes (102~3613) in the MLG.
Abundance in Group 1: decreased abundance in Colorectal Cancer
NCBI | Quality Control | Links |
---|---|---|
Actinomyces viscosus | ||
Clostridium sp. | ||
Streptococcus mutans | ||
Streptococcus thermophilus | ||
Bifidobacterium animalis |
Revision editor(s): Jeshudy
Signature 2
Source: Figure 4c
Description: Control versus carcinoma (n = 55 and 41). For all MLGs containing >100 genes, the direction of enrichment was determined by Wilcoxon rank-sum test (P < 0.05, Supplementary Data 3). Size of the nodes scales with the number of genes (102~3613) in the MLG.
Abundance in Group 1: increased abundance in Colorectal Cancer
Revision editor(s): Jeshudy
Experiment 3
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Advanced Colorectal Adenoma
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- colorectal adenoma patients The study was conducted both in participants of a health screening programme according to national screening recommendations for CRC49 as well as in patients with suspected CRC undergoing colonoscopy as part of the clinical workup at the Department of Internal Medicine, Oberndorf Hospital.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 42
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Richness Number of species
- increased
Signature 1
Source: Figure 4b
Description: Advanced adenoma vs carcinoma (n = 42, 41).
Abundance in Group 1: decreased abundance in Colorectal Cancer
NCBI | Quality Control | Links |
---|---|---|
Clostridium sp. | ||
Streptococcus thermophilus | ||
Bifidobacterium animalis | ||
Actinomyces viscosus |
Revision editor(s): Jeshudy
Signature 2
Source: Figure 4b
Description: Advanced adenoma vs carcinoma (n = 42, 41).
Abundance in Group 1: increased abundance in Colorectal Cancer
Revision editor(s): Jeshudy